ArticleInternational journal of genomics2025
Cooling Blood and Detoxicating Formula Treats Psoriasis Through RHCG-Related Mechanisms.
Article in International journal of genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Luteolin Disrupts Keratinocyte-Dendritic Cell Communication in Psoriasis by Targeting Rh Family C Glycoprotein.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the therapeutic potential of the cooling blood and detoxicating formula (CBDF) in the treatment of psoriasis, emphasizing its anti-inflammatory properties and its interaction with RHCG-related mechanisms. Psoriasis, a complex skin disorder characterized by abnormal keratinocyte proliferation and immune system dysregulation, remains challenging to treat effectively. Utilizing advanced techniques including network pharmacology, single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics, this research identifies key active components in CBDF-quercetin and kaempferol-that influence critical inflammatory pathways. In experimental models, CBDF significantly alleviates psoriasis symptoms, reducing keratinocyte differentiation abnormalities and dendritic cell (DC) activation. Molecular docking studies demonstrate strong interactions between RHCG and the active ingredients in CBDF. These findings suggest that CBDF exerts its effects through a multifaceted approach, with RHCG identified as a pivotal target. While the results are promising, further clinical validation and mechanistic research are needed. This study underscores the potential of CBDF as a treatment for psoriasis, blending traditional medicine with modern molecular insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.